Compare Adaptive Biotechnologies Corp (ADPT) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance

ADPT trades at $24.46, down 3.66% today but remains near its 52-week high. The stock shows bullish technical signals with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025, while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to a pure-play MRD diagnostics business following the Immune Medicine separation has generated positive investor sentiment, with 65% of analysts maintaining buy ratings.

Outlook remains cautiously optimistic as ADPT's MRD business demonstrates strong growth potential with 49% YoY revenue expansion. Key risks include persistent negative profitability metrics and execution challenges during the business separation. The consensus price target of $25.50 suggests modest upside potential from current levels, contingent on continued operational improvement.

REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $77.03, up 0.4% today, with a bullish technical signal from moving averages but overbought RSI levels. The fund provides exposure to 38 global rare earth and strategic metals companies, heavily weighted toward China, and exhibits high volatility around 50% annually. Recent news highlights U.S. efforts to build rare earth supply chain independence, with Energy Fuels beginning construction on a Utah plant expansion in late July 2026.

Outlook is driven by geopolitical shifts reducing reliance on Chinese rare earths, offering long-term growth potential, but risks include high volatility, China concentration, and sensitivity to trade policies. The fund suits aggressive investors comfortable with sector-specific turbulence and macroeconomic uncertainties.